Therapies based on glucagon-like peptide-1 (GLP-1) reduce rates of cardiovascular and chronic kidney disease in people with type 2 diabetes and/or obesity, with ongoing clinical trials investigating their effects in people with metabolic liver disease, arthritis, and both substance use and neurodegenerative disorders
These approaches aim to reduce oxidative stress, restore antioxidant defenses, and prevent iron-driven cell death
It works like this: After you eat, gut peptides begin stimulating insulin secretion in response to the typical rise in blood glucose post-meal
Scientific research on sciatica prevalence shows this combination affects 10-40% of people at some point, with most cases happening in your thirties
MicroRNA and diabetic retinopathy (DR) T2D is a progressive condition that, if unmanaged, can result in severe consequences, including macrovascular and microvascular disorders [115]